The penetration of amphotericin B from an Intralipid® formulation into fibrin loci in a rabbit model of candidiasis

The kinetics of amphotericin B (AMB) concentrations in plasma and interstitial fluid were studied in an experimental model of Candida albicans infection in rabbits. Rabbits were infected by subcutaneously implanted fibrin clots containing the yeast. Three groups of five rabbits received a 4 mg kg−1 AMB infusion. AMB (Fungizone®) was dissolved in 5% glucose (group I) or in 20% Intralipid® at a final concentration of 1.5 (group II) or 3 mg mL−1 (group III). AMB was measured by liquid chromatography in plasma and in trypsin‐dissolved fibrin clots up to 72 h after the infusion. No significant differences in AMB plasma and interstitial‐fluid concentration kinetics between the three modes of administration were found. AMB penetration into fibrin clots was slow, with no significant differences between treatments. Thus, formulation of AMB in Intralipid does not modify either the drug's interstitial or plasma kinetics at equivalent doses.

[1]  R. Farinotti,et al.  In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid , 1994, Antimicrobial Agents and Chemotherapy.

[2]  J. Bolard,et al.  Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses , 1994, Antimicrobial Agents and Chemotherapy.

[3]  O. Casasnovas,et al.  Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. , 1993, The Journal of antimicrobial chemotherapy.

[4]  P. Legrand,et al.  Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes , 1992, Antimicrobial Agents and Chemotherapy.

[5]  D. Crommelin,et al.  Liposomal and Lipid Formulations of Amphotericin B , 1992, Clinical pharmacokinetics.

[6]  O. Casasnovas,et al.  [Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy]. , 1992, Pathologie-biologie.

[7]  I. Bakker-Woudenberg,et al.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans , 1991, Antimicrobial Agents and Chemotherapy.

[8]  R. van Furth,et al.  Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice , 1989, Antimicrobial Agents and Chemotherapy.

[9]  G. Poste,et al.  An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. , 1988, The Journal of infectious diseases.

[10]  S. Davis,et al.  The structure of colloidal formulations of amphotericin B , 1988 .

[11]  M. C. Popescu,et al.  Unusual lipid structures selectively reduce the toxicity of amphotericin B. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Powderly,et al.  Amphotericin B-resistant yeast infection in severely immunocompromised patients. , 1988, The American journal of medicine.

[13]  R. Juliano,et al.  Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. , 1987, Molecular pharmacology.

[14]  J. Bolard.  How do the polyene macrolide antibiotics affect the cellular membrane properties? , 1986, Biochimica et biophysica acta.

[15]  W. Holleran,et al.  Empiric amphotericin B therapy in patients with acute leukemia. , 1985, Reviews of infectious diseases.

[16]  R. Guinet,et al.  Reproducible measurement of amphotericin B in serum by high-performance liquid chromatography in alkaline buffer. , 1985, Journal of chromatography.

[17]  M. Barza,et al.  Penetration of antibiotics into fibrin loci in vivo. I. Comparison of penetration of ampicillin into fibrin clots, abscesses, and "interstitial fluid". , 1974, The Journal of infectious diseases.